Vor Biopharma (NASDAQ:VOR) Downgraded by Wall Street Zen to “Sell”

Vor Biopharma (NASDAQ:VOR) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other research analysts have also issued research reports about the stock. Citigroup raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, October 15th. William Blair assumed coverage on Vor Biopharma in a research report on Wednesday, October 21st. They set an “outperform” rating on the stock. Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Finally, Wedbush raised their price objective on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Vor Biopharma has an average rating of “Moderate Buy” and an average target price of $38.00.

Vor Biopharma Trading Down 5.9%

Vor Biopharma stock opened at $19.68 on Friday. Vor Biopharma has a fifty-two week low of $6.50 and a fifty-two week high of $26.76. The firm has a 50 day moving average price of $20.75 and a 200 day moving average price of $17.33.

Vor Biopharma (NASDAQ:VOR) last announced its earnings results on Friday, October 30th. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.64). As a group, equities research analysts anticipate that Vor Biopharma will post -2.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of VOR. Bank of America Corp DE raised its position in Vor Biopharma by 28,408.1% during the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after buying an additional 112,496 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Vor Biopharma in the first quarter valued at about $2,298,000. Braidwell LP boosted its holdings in shares of Vor Biopharma by 22.8% in the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock valued at $10,551,000 after acquiring an additional 106,330 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Vor Biopharma in the second quarter valued at about $499,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Vor Biopharma during the second quarter worth about $1,799,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.